Featured Content


We're under way...

The ASCO '13 annual meeting abstracts were just released on Wednesday, and we're seeing a lot of media coverage. OBR covered the ASCO presscast the same day and is featured in a blog titled "ASCO '13: Studies Highlight Resource utilization, Immunotherapy, Targeted Therapy, and Physical Fitness".

Howard Sandler, MD, MS, FASTRO
Professor and Chair, Department of Radiation Oncology

Testicular Cancer Treatment May Not Require Radiation

(Bloomberg) May 16, 2013 - Chemotherapy, radiation and the use of radioactive follow-up tests aren't needed for some cancers, according to two studies that add to a growing debate on ways to lessen side effects and lower patient costs.

Commentary: Data from ASCO suggests that active surveillance is reasonable for Stage I seminomas after orchiectomy. Given the...

 1 comments  Add a comment
 facebook share button  twitter share button  linkedin share button



OBR Daily   Our free daily oncology focused e-news service.
Subscribe»  |  Search Archives»

Today's News

Sanofi Reports Positive Topline Results from Pivotal Phase III JAKARTA Study for JAK2 Inhibitor in Myelofibrosis

(Sanofi) May 17, 2013 - Sanofi announced today that the pivotal study, JAKARTA, examining the selective JAK2 inhibitor SAR302503 for myelofibrosis (MF), met its primary endpoint in both dose groups.
read corporate press release »

A Dilemma in the Search for Breast Cancer

(Wall Street Journal) May 16, 2013 - Doctors are divided about how best to scan "dense" breasts. A look at the options.
read article (paid subscription required) »

Gene-Testing Dispute Focuses on How Much a Patient Should Know

(Bloomberg) May 16, 2013 - Should patients undergoing broad DNA testing for a specific ailment be told of unexpected findings that signal risk of cancer or other serious diseases, even if they don't request the information?
read article »

 

View ALL News »




News Story Commentary By Academic and Community Oncologists



Testicular Cancer Treatment May Not Require Radiation (Bloomberg)

Data from ASCO suggests that active surveillance is reasonable for Stage I seminomas after orchiectomy. Given the...posted by: Howard Sandler, MD, MS, FASTRO

Bayer, Algeta Win U.S. Approval for Prostate Cancer Drug (Bloomberg)

This is an important development, finally bringing an FDA approval to match with the overwhelming evidence supporting...posted by: H. Jack, West, MD

Oral Parity Update 2013: Federal Edition (ACCCBuzz)

Oral parity laws are becoming more common. The intent is to maintain access to care regardless of whether the...posted by: Thomas, Marsland, MD

Oral Parity Update 2013: Federal Edition (ACCCBuzz)

Just as an FYI, in most States, the oral parity regulations only apply to the fully insured groups, meaning small...posted by: Winston, Wong, PharmD

Many Medical Guidelines Don't Consider Costs (Reuters Health)

I think this comment is somewhat ridiculous. Pathways and guidelines are supposed to be evidence-based and that...posted by: Thomas Marsland, MD






OBR Training


Learn more about the OBR training platform, developed to provide an in-depth understanding of the unique business dynamics of today's oncology landscape.




OBR Job Board

Novocure has posted 3 new jobs and Sarah Cannon has 1 job posted on the OBR Job Board.

View all job listings here


KH_Pre-ASCO_Webinar_300x250

The most comprehensive and up-to-date oncology pipeline information on the web!
OBR Pipeline Online™






View company profiles, indexes, and streaming stock quotes of over 200 oncology focused companies.

Winners/Losers

Symbol  %Δ
PVCT +12.58%
APRI +7.28%
AVEO +7.12%
PARD -8.70%
ZIOP -5.11%
BDSI -3.27%


    


OBR Radar

View upcoming pivotal oncology events such as PDUFA dates, ODAC dates, and announcement of phase III clinical trial results


Date: June 3, 2013
Company: GlaxoSmithKline
Product: dabrafenib

Date: June 5, 2013
Company: Celgene Corp.
Product: Revlimid® (lenalidomide)

Date: July 15, 2013
Company: Boehringer Ingelheim Pharmaceuticals
Product: afatinib (BIBW 2992)

See All OBR Radar items»